Patent intelligence · US
US 2017340593
MEDICAMENTS FOR SLOWING PARKINSON'S DISEASE
MEDICAMENTS FOR SLOWING PARKINSON'S DISEASE
Patent details — US 2017340593
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 30, 2017
- Expiration
- Nov 25, 2037
- Applicant
- BIAL - PORTELA & CA S A [PT]
- CPC classes
- A61K 31/ 165 A I, A61K 31/ 198 A I, A61K 31/ 4439 A I, A61K 45/ 06 A I
Quick answer
US 2017340593 (MEDICAMENTS FOR SLOWING PARKINSON'S DISEASE) is held by BIAL - PORTELA & CA S A [PT]. Status: granted. Granted Nov 30, 2017. Expires Nov 25, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIAL - PORTELA & CA S A [PT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 165 A I, A61K 31/ 198 A I, A61K 31/ 4439 A I, A61K 45/ 06 A I, A61K/31165, A61K/31198
More from BIAL - PORTELA & CA S A [PT]
Related pharmaceutical patents in our USPTO index.
-
WO 2026106499
ANTAGONISTES DU RÉCEPTEUR DE L'ORÉXINE : COMPOSÉS 2-AZABICYCLIQUES
granted -
WO 2026015039
THÉRAPIE GÉNIQUE POUR LE TRAITEMENT DE L'ENCÉPHALOPATHIE ÉPILEPTIQUE ASSOCIÉE À LA SYNGAP1
granted -
WO 2025211975
AGONISTES DU RÉCEPTEUR DE L'OREXINE
granted -
WO 2025023852
ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE
granted -
WO 2025023851
ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE
granted -
WO 2024242579
RÉGIMES DE TRAITEMENT DE LA MALADIE DE PARKINSON IDIOPATHIQUE PRÉCOCE
granted -
AU 2023244944
PRODRUGS OF OPICAPONE
granted -
WO 2024039256
RÉGIMES THÉRAPEUTIQUES POUR LA MALADIE DE PARKINSON
granted
Frequently asked questions
What is US patent 2017340593?
US 2017340593 (MEDICAMENTS FOR SLOWING PARKINSON'S DISEASE) is held by BIAL - PORTELA & CA S A [PT]. Status: granted. Granted Nov 30, 2017. Expires Nov 25, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2017340593?
BIAL - PORTELA & CA S A [PT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2017340593 expire?
Our index shows an expiration date of Nov 25, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.